Rhode IslandH74242026 Regular SessionHouse

AN ACT RELATING TO BUSINESSES AND PROFESSIONS -- COLLABORATIVE PHARMACY PRACTICE .

Sponsored By: Joseph J. Solomon, Jr. (Democratic)

Signed by Governor

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 2 benefits, 0 costs, 1 mixed.

Faster, broader pharmacist care agreements

Beginning July 1, 2026, pharmacists can team up with more types of prescribers, not just doctors. The agreement must be written and signed, and it is voluntary. Care can start once all required paperwork is complete; no board pre-approval is needed. Agreements must follow clinical guidelines, be reviewed and signed each year, and parties must answer board questions. The health department may set limits and conditions. The collaborating provider can approve the pharmacist’s relevant training, like a residency or board certification. A pharmacy degree or equivalent advanced training is still required.

Pharmacists can run more tests

Beginning July 1, 2026, if your pharmacist has a signed collaborative agreement, they can order and review lab tests tied to your medicines. They must follow approved protocols for the practice setting, and this activity is not a diagnostic service. They can take vital signs like blood pressure, pulse, weight, temperature, height, and breathing rate when needed for your care. Limited-function tests now mean those listed by federal rules as CLIA‑waived.

Narrower legal immunity in pharmacy oversight

Beginning July 1, 2026, the former collaborative practice committee is eliminated and no longer has explicit legal immunity. The director of health, the state pharmacy board, their staff, and witnesses still have immunity for good‑faith actions and statements under this chapter. This tightens immunity around committee‑type actions while keeping protections for good‑faith regulators.

Sponsors & Cosponsors

Sponsor

Joseph J. Solomon, Jr.
Democratic • House

Cosponsors

Stephen M. Casey
Democratic • House
Julie A. Casimiro
Democratic • House

Roll Call Votes

All Roll Calls

Yes: 65 • No: 0

House vote • 4/16/2026

COLLABORATIVE PHARMACY PRACTICE PASSAGE